

# Tuberculosis profile: Iran (Islamic Republic of)

Population 2021: 88 million

## Estimates of TB burden\*, 2021

	Number	(Rate per 100 000 population)
Total TB incidence	10 000 (7 800-13 000)	12 (8.8-15)
HIV-positive TB incidence	220 (160-300)	0.25 (0.18-0.34)
MDR/RR-TB incidence**	220 (51-390)	0.25 (0.06-0.45)
HIV-negative TB mortality	880 (850-920)	1 (0.97-1)
HIV-positive TB mortality	85 (59-120)	0.1 (0.07-0.13)

## Estimated proportion of TB cases with MDR/RR-TB\*, 2021

New cases	1.8% (0.77-3.5)
Previously treated cases	7% (4.2-11)

## Universal health coverage and social protection\*

TB treatment coverage (notified/estimated incidence), 2021	60% (46-80)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2021	10% (7-12)

## TB case notifications, 2021

Total new and relapse	6 199
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	91%
- % pulmonary	77%
- % bacteriologically confirmed ^	86%
- % children aged 0-14 years	4%
- % women (aged ≥15 years)	43%
- % men (aged ≥15 years)	53%
Total cases notified	6 315

## TB/HIV care in new and relapse TB patients, 2021

	Number	(%)
Patients with known HIV status who are HIV-positive	120	2.1%
- on antiretroviral therapy	110	92%

## Drug-resistant TB care\*\*, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	47%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	81%
Laboratory-confirmed cases - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	39
Patients started on treatment - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^^	34
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	1
Patients started on treatment - pre-XDR-TB or XDR-TB ^^^	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	18

## Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2020	84%	5 958
Previously treated cases, excluding relapse, registered in 2020	73%	101
HIV-positive TB cases registered in 2020	63%	120
MDR/RR-TB cases started on second-line treatment in 2019	54%	28
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019		0


## TB preventive treatment, 2021

% of HIV-positive people (newly enrolled in care) on preventive treatment	5.2%
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100-100)


## Funding for TB

Funding for TB, 2021 (US\$ millions)	0
- % domestic funding	
- % international funding	


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




## HIV-negative TB mortality (Rate per 100 000 population per year)




## Incidence, Notified cases by age group and sex, 2021



## Cases attributable to five risk factors, 2021



## Funding for TB (US\$ millions)



\* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.  
\*\* RR is TB resistant to rifampicin (R), MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone  
^ Calculated for pulmonary cases only  
^^ Includes cases with unknown previous TB treatment history  
^^^ Includes patients diagnosed before 2021 and patients who were not laboratory-confirmed

---

Generated 2022-12-15 by the World Health Organization (<https://www.who.int/teams/global-tuberculosis-programme/data>)